Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
oleh: Linda van Oosten, Jort J. Altenburg, Cyrielle Fougeroux, Corinne Geertsema, Fred van den End, Wendy A. C. Evers, Adrie H. Westphal, Simon Lindhoud, Willy van den Berg, Daan C. Swarts, Laurens Deurhof, Andreas Suhrbier, Thuy T. Le, Shessy Torres Morales, Sebenzile K. Myeni, Marjolein Kikkert, Adam F. Sander, Willem Adriaan de Jongh, Robert Dagil, Morten A. Nielsen, Ali Salanti, Max Søgaard, Timo M. P. Keijzer, Dolf Weijers, Michel H. M. Eppink, René H. Wijffels, Monique M. van Oers, Dirk E. Martens, Gorben P. Pijlman
| Format: | Article |
|---|---|
| Diterbitkan: | American Society for Microbiology 2021-10-01 |
Deskripsi
Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19.